Marshall Wace, LLP Insmed Inc Transaction History

Marshall Wace, LLP

$77.3 Billion
Q3 2024

A detailed history of Marshall Wace, LLP transactions in Insmed Inc stock. As of the latest transaction made, Marshall Wace, LLP holds 771,211 shares of INSM stock, worth $56.6 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares

771,211

Previous 1,249,351 38.27%

Holding current value

$56.6 Million

Previous $83.7 Million 32.74%

% of portfolio

0.07%

Previous 0.12%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$62.0 - $79.01 $29.6 Million - $37.8 Million	-478,140 Reduced 38.27%	771,211 $56.3 Million
Q2 2024 Aug 14, 2024	SELL	$22.0 - $69.71 $1.78 Million - $5.63 Million	-80,697 Reduced 6.07%	1,249,351 $83.7 Million
Q1 2024 May 15, 2024	SELL	$25.72 - $29.94 $2.82 Million - $3.29 Million	-109,721 Reduced 7.62%	1,330,048 $36.1 Million
Q4 2023 Feb 14, 2024	BUY	$23.42 - $31.74 $20.5 Million - $27.7 Million	874,006 Added 154.48%	1,439,769 $44.6 Million
Q3 2023 Nov 14, 2023	BUY	$19.86 - $26.93 $2.37 Million - $3.22 Million	119,549 Added 26.79%	565,763 $14.3 Million
Q2 2023 Aug 14, 2023	BUY	$16.44 - $21.1 $7.34 Million - $9.42 Million	446,214 New	446,214 $9.42 Million
Q4 2020 Feb 16, 2021	SELL	$31.45 - $40.54 $841,507 - $1.08 Million	-26,757 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$26.0 - $34.5 $695,682 - $923,116	26,757 New	26,757 $860,000
Q1 2020 May 15, 2020	SELL	$13.63 - $33.98 $272,286 - $678,818	-19,977 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$16.12 - $24.98 $6.96 Million - $10.8 Million	-431,473 Reduced 95.57%	19,977 $477,000
Q3 2019 Nov 14, 2019	BUY	$15.49 - $25.78 $6.99 Million - $11.6 Million	451,450 New	451,450 $7.96 Million

Others Institutions Holding INSM

# of Institutions

467

Shares Held

182M

Call Options Held

2.27M

Put Options Held

3.33M

View Full List

About INSMED Inc

Ticker INSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,476,992
Market Cap $9.94B
Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...

More about INSM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account

Marshall Wace, LLP Insmed Inc Transaction History